HDAC6 and neoplasm: The leading compound is the HDAC6 inhibitor, which acts via the hyperacetylation of MYC (K148ac), strongly inducing its proteasomal degradation via the parallel sensitization of tumor cells to ionizing radiation [53,171,172,173].